Ruxolitinib Switch-Maintenance Prophylaxis of GVHD
Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 40 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Incyte Corporation
- Tags
- JAK1 Inhibitor, Tyrosine Kinase (TK) Inhibitor, JAK2 Inhibitor, Randomization, Maintenance
- Trial Type
- Supportive
- Last Update
- SparkCures ID
- 2223
- NCT Identifier
- NCT07359859
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.